Progesterone receptor-cyclin D1 complexes induce cell cycle-dependent transcriptional programs in breast cancer cells

Molecular Endocrinology

Volumn 28, Issue 4, 2014, Pages 442-457

  Dressing, Gwen E ^a   Knutson, Todd P ^a   Schiewer, Matthew J ^b   Daniel, Andrea R ^a   Hagan, Christy R ^a   Diep, Caroline H ^a   Knudsen, Karen E ^b   Lange, Carol A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ANTIGESTAGEN; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; GESTAGEN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 22; LIGAND; MESSENGER RNA; PROGESTERONE RECEPTOR; ROSCOVITINE; TAMOXIFEN; TRANSCRIPTION FACTOR SP1; CDK2 PROTEIN, HUMAN; CELL EXTRACT; HSPB8 PROTEIN, HUMAN; PHOSPHOSERINE; PROTEIN SERINE THREONINE KINASE;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER GROWTH; CARCINOMA CELL; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL LINE; CELL LYSATE; COMPLEX FORMATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION PROFILING; GENE TARGETING; GENETIC TRANSCRIPTION; HORMONE ACTION; INTERACTIONS WITH DNA; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; PURIFICATION; WHOLE CELL; ANIMAL; BREAST TUMOR; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL CYCLE; CELL EXTRACTS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; CYCLIN D1; CYCLIN-DEPENDENT KINASE 2; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAT-SHOCK PROTEINS; HUMANS; PHOSPHORYLATION; PHOSPHOSERINE; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, PROGESTERONE; TRANSCRIPTION, GENETIC;

EID: 84897944038     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2013-1196     Document Type: Article

References (83)

1. Sicinski P, Donaher JL, Parker SB, et al. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell. 1995; 82: 621-630.
2. Mulac-Jericevic B, Lydon JP, DeMayo FJ, Conneely OM. Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. Proc Natl Acad Sci USA. 2003; 100: 9744-9749.
3. Beleut M, Rajaram RD, Caikovski M, et al. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci USA. 2010; 107: 2989-2994.
4. Kenny FS, Hui R, Musgrove EA, et al. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptorpositive breast cancer. Clin Cancer Res. 1999; 5: 2069-2076.
5. Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol. 2005; 23: 4215-4224.
6. Faivre EJ, Lange CA. Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Srcdependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells. Mol Cell Biol. 2007; 27: 466-480.
7. Giulianelli S, Vaqué JP, Soldati R, et al. Estrogen receptor α mediates progestin-induced mammary tumor growth by interacting with progesterone receptors at the cyclin D1/MYC promoters. Cancer Res. 2012; 72: 2416-2427.
8. Lamb J, Ladha MH, McMahon C, Sutherland RL, Ewen ME. Regulation of the functional interaction between cyclin D1 and the estrogen receptor. Mol Cell Biol. 2000; 20: 8667-8675.
9. Zwijsen RM, Wientjens E, Klompmaker R, et al. CDK-independent activation of estrogen receptor by cyclin D1. Cell. 1997; 88: 405-415.
10. Zwijsen RM, Buckle RS, Hijmans EM, Loomans CJ, Bernards R. Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Dev. 1998; 12: 3488-3498.
11. 2-terminal domain inhibits activation of function 2 association and reveals dual roles for AR corepression. Mol Endocrinol. 2005; 19: 607-620.
12. Petre-Draviam CE, Williams EB, Burd CJ, et al. A central domain of cyclin D1 mediates nuclear receptor corepressor activity. Oncogene. 2005; 24: 431-444.
13. Daniel AR, Knutson TP, Lange CA. Signaling inputs to progesterone receptor gene regulation and promoter selectivity. Mol Cell Endocrinol. 2009; 308: 47-52.
14. Groshong SD, Owen GI, Grimison B, et al. Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). Mol Endocrinol. 1997; 11: 1593-1607.
15. Faivre E, Skildum A, Pierson-Mullany L, Lange CA. Integration of progesterone receptor mediated rapid signaling and nuclear actions in breast cancer cell models: role of mitogen-activated protein kinases and cell cycle regulators. Steroids. 2005; 70: 418-426.
16. Narayanan R, Adigun AA, Edwards DP, Weigel NL. Cyclin-dependent kinase activity is required for progesterone receptor function: novel role for cyclin A/Cdk2 as a progesterone receptor coactivator. Mol Cell Biol. 2005; 25: 264-277.
17. Moore NL, Narayanan R, Weigel NL. Cyclin dependent kinase 2 and the regulation of human progesterone receptor activity. Steroids. 2007; 72: 202-209.
18. Dou QP, Molnar G, Pardee AB. Cyclin D1/cdk2 kinase is present in a G1 phase-specific protein complex Yi1 that binds to the mouse thymidine kinase gene promoter. Biochem Biophys Res Commun. 1994; 205: 1859-1868.
19. Dulić V, Drullinger LF, Lees E, Reed SI, Stein GH. Altered regulation of G1 cyclins in senescent human diploid fibroblasts: accumulation of inactive cyclin E-Cdk2 and cyclin D1-Cdk2 complexes. Proc Natl Acad Sci USA. 1993; 90: 11034-11038.
20. Sweeney KJ, Swarbrick A, Sutherland RL, Musgrove EA. Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells. Oncogene. 1998; 16: 2865-2878.
21. Chytil A, Waltner-Law M, West R, et al. Construction of a cyclin D1-Cdk2 fusion protein to model the biological functions of cyclin D1-Cdk2 complexes. J Biol Chem. 2004; 279: 47688-47698.
22. Yang C, Trent S, Ionescu-Tiba V, et al. Identification of cyclin D1-and estrogen-regulated genes contributing to breast carcinogenesis and progression. Cancer Res. 2006; 66: 11649-11658.
23. Lamb J, Ramaswamy S, Ford HL, et al. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell. 2003; 114: 323-334.
24. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: Cyclin D1: normal and abnormal functions. Endocrinology. 2004; 145: 5439-5447.
25. Bienvenu F, Jirawatnotai S, Elias JE, et al. Transcriptional role of cyclin D1 in development revealed by a genetic-proteomic screen. Nature. 2010; 463: 374-378.
26. Faivre EJ, Daniel AR, Hillard CJ, Lange CA. Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors. Mol Endocrinol. 2008; 22: 823-837.
27. Horwitz KB, Mockus MB, Lessey BA. Variant T47D human breast cancer cells with high progesterone-receptor levels despite estrogen and antiestrogen resistance. Cell. 1982; 28: 633-642.
28. Sartorius CA, Groshong SD, Miller LA, et al. New T47D breast cancer cell lines for the independent study of progesterone B-and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP. Cancer Res. 1994; 54: 3868-3877.
29. Pierson-Mullany LK, Lange CA. Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2. Mol Cell Biol. 2004; 24; 10542-10557.
30. Hagan CR, Regan TM, Dressing GE, Lange CA. ck2-dependent phosphorylation of progesterone receptors (PR) on Ser81 regulates PR-B isoform-specific target gene expression in breast cancer cells. Mol Cell Biol. 2011; 31: 2439-2452.
31. Oliveros JC VENNY. An interactive tool for comparing lists with Venn diagrams. BioinfoGP; 2007. http://bioinfogp. cnb. csic. es/tools/venny/index. html. Accessed March 14, 2014.
32. Pierson-Mullany LK, Lange CA. Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2. Mol Cell Biol. 2004; 24: 10542-10557.
33. Weigel NL, Moore NL. Cyclins, cyclin dependent kinases, and regulation of steroid receptor action. Mol Cell Endocrinol. 2007; 265: 157-161.
34. Moore NL, Weigel NL. Regulation of progesterone receptor activity by cyclin dependent kinases 1 and 2 occurs in part by phosphorylation of the SRC-1 carboxyl-terminus. Int J Biochem Cell Biol. 2011; 43: 1157-1167.
35. Knotts TA, Orkiszewski RS, Cook RG, Edwards DP, Weigel NL. Identification of a phosphorylation site in the hinge region of the human progesterone receptor and additional amino-terminal phosphorylation sites. J Biol Chem. 2001; 276: 8475-8483.
36. Lange CA, Richer JK, Shen T, Horwitz KB. Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogen-activated protein kinase pathways. J Biol Chem. 1998; 273: 31308-31316.
37. Qiu M, Olsen A, Faivre E, Horwitz KB, Lange CA. Mitogen-activated protein kinase regulates nuclear association of human progesterone receptors. Mol Endocrinol. 2003; 17: 628-642.
38. Daniel AR, Lange CA. Protein kinases mediate ligand-independent derepression of sumoylated progesterone receptors in breast cancer cells. Proc Natl Acad Sci USA. 2009; 106: 14287-14292.
39. Knutson TP, Daniel AR, Fan D, et al. Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression. Breast Cancer Res. 2012; 14: R95.
40. Mootha VK, Lindgren CM, Eriksson KF, et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003; 34: 267-273.
41. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genomewide expression profiles. Proc Natl Acad Sci USA. 2005; 102: 15545-15550.
42. Smid M, Wang Y, Zhang Y, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008; 68: 3108-3114.
43. Landis MD, Seachrist DD, Montañez-Wiscovich ME, Danielpour D, Keri RA. Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-β signaling in ErbB2/Neu-induced tumors from transgenic mice. Oncogene. 2005; 24: 5173-5190.
44. Doane AS, Danso M, Lal P, et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene. 2006; 25: 3994-4008.
45. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2: 401-404.
46. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6: pl1.
47. Gonzalez-Malerva L, Park J, Zou L, et al. High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy. Proc Natl Acad Sci USA. 2011; 108: 2058-2063.
48. Stebbing J, Filipovic A, Lit LC, et al. LMTK3 is implicated in endocrine resistance via multiple signaling pathways. Oncogene. 2013; 32: 3371-3380.
49. Opitz OG, Rustgi AK. Interaction between Sp1 and cell cycle regulatory proteins is important in transactivation of a differentiationrelated gene. Cancer Res. 2000; 60: 2825-2830.
50. Chu S. Transcriptional regulation by post-transcriptional modification-Role of phosphorylation in Sp1 transcriptional activity. Gene. 2012; 508: 1-8.
51. Tang Q, Chen Y, Meyer C, et al. A comprehensive view of nuclear receptor cancer cistromes. Cancer Res. 2011; 71: 6940-6947.
52. Petre-Draviam CE, Cook SL, Burd CJ, Marshall TW, Wetherill YB, Knudsen KE. Specificity of cyclin D1 for androgen receptor regulation. Cancer Res. 2003; 63: 4903-4913.
53. Hinds PW, Dowdy SF, Eaton EN, Arnold A, Weinberg RA. Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci USA. 1994; 91: 709-713.
54. Wright RH, Castellano G, Bonet J, et al. CDK2-dependent activation of PARP-1 is required for hormonal gene regulation in breast cancer cells. Genes Dev. 2012; 26: 1972-1983.
55. Daniel AR, Faivre EJ, Lange CA. Phosphorylation-dependent antagonism of sumoylation derepresses progesterone receptor action in breast cancer cells. Mol Endocrinol. 2007; 21: 2890-2906.
56. Dressing GE, Lange CA. Integrated actions of progesterone receptor and cell cycle machinery regulate breast cancer cell proliferation. Steroids. 2009; 74: 573-576.
57. Yu IJ, Spector DL, Bae YS, Marshak DR. Immunocytochemical localization of casein kinase II during interphase and mitosis. J Cell Biol. 1991; 114: 1217-1232.
58. 1-phase of the cell cycle does not depend on the ERK1/2 pathway but requires active protein synthesis. Arch Biochem Biophys. 2002; 406: 165-172.
59. Chambard JC, Lefloch R, Pouysségur J, Lenormand P. ERK implication in cell cycle regulation. Biochim Biophys Acta. 2007; 1773: 1299-1310.
60. Satyanarayana A, Kaldis P. Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene. 2009; 28: 2925-2939.
61. Vallejo G, Ballaré C, Barañao JL, Beato M, Saragüeta P. Progestin activation of nongenomic pathways via cross talk of progesterone receptor with estrogen receptor β induces proliferation of endometrial stromal cells. Mol Endocrinol. 2005; 19: 3023-3037.
62. Carnevale RP, Proietti CJ, Salatino M, et al. Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways. Mol Endocrinol. 2007; 21: 1335-1358.
63. Narayanan R, Edwards DP, Weigel NL. Human progesterone receptor displays cell cycle-dependent changes in transcriptional activity. Mol Cell Biol. 2005; 25: 2885-2898.
64. Yang C, Chen L, Li C, Lynch MC, Brisken C, Schmidt EV. Cyclin D1 enhances the response to estrogen and progesterone by regulating progesterone receptor expression. Mol Cell Biol. 2010; 30: 3111-3125.
65. Béguelin W, Díaz Flaqué MC, Proietti CJ, et al. Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 function as a coactivator of Stat3. Mol Cell Biol. 2010; 30: 5456-5472.
66. Coqueret O. Linking cyclins to transcriptional control. Gene. 2002; 299: 35-55.
67. Casimiro MC, Crosariol M, Loro E, et al. ChIP sequencing of cyclin D1 reveals a transcriptional role in chromosomal instability in mice. J Clin Invest. 2012; 122: 833-843.
68. Bostrom P, Söderström M, Palokangas T, et al. Analysis of cyclins A, B1, D1 and E in breast cancer in relation to tumour grade and other prognostic factors. BMC Res Notes. 2009; 2: 140.
69. Zhu J, Sen S, Wei C, Frazier ML. Cyclin D1b represses breast cancer cell growth by antagonizing the action of cyclin D1a on estrogen receptor α-mediated transcription. Int J Oncol. 2010; 36: 39-48.
70. Lin HM, Zhao L, Cheng SY. Cyclin D1 is a ligand-independent co-repressor for thyroid hormone receptors. J Biol Chem. 2002; 277: 28733-28741.
71. Graham JD, Mote PA, Salagame U, et al. DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. Endocrinology. 2009; 150: 3318-3326.
72. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490: 61-70.
73. Conneely OM, Jericevic BM, Lydon JP. Progesterone receptors in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia. 2003; 8: 205-214.
74. Kariagina A, Xie J, Leipprandt JR, Haslam SZ. Amphiregulin mediates estrogen, progesterone, and EGFR signaling in the normal rat mammary gland and in hormone-dependent rat mammary cancers. Horm Cancer. 2010; 1: 229-244.
75. Jonat W, Bachelot T, Ruhstaller T, Kuss I, Reimann U, Robertson JF. Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer. Ann Oncol. 2013; 24: 2543-2548.
76. Lanari C, Wargon V, Rojas P, Molinolo AA. Antiprogestins in breast cancer treatment: are we ready? Endocr Relat Cancer. 2012; 19: R35-50.
77. Lange CA, Yee D. Progesterone and breast cancer. Womens Health (Lond Engl). 2008; 4: 151-162.
78. Johnston SR, Saccani-Jotti G, Smith IE, et al. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifenresistant human breast cancer. Cancer Res. 1995; 55: 3331-3338.
79. Encarnación CA, Ciocca DR, McGuire WL, Clark GM, Fuqua SA, Osborne CK. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat. 1993; 26: 237-246.
80. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009; 9: 631-643.
81. Stendahl M, Kronblad A, Rydén L, Emdin S, Bengtsson NO, Landberg G. Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br J Cancer. 2004; 90: 1942-1948.
82. Shen T, Horwitz KB, Lange CA. Transcriptional hyperactivity of human progesterone receptors is coupled to their ligand-dependent down-regulation by mitogen-activated protein kinase-dependent phosphorylation of serine 294. Mol Cell Biol. 2001; 21: 6122-6131.
83. Lange CA, Shen T, Horwitz KB. Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc Natl Acad Sci USA. 2000; 97: 1032-1037.